secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001127537-24-000073
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx reports record Q2 revenue $20.8M (+21% YoY); net loss narrows to $15.3M
-------------------------------------------------------------------------------

- Worldwide revenue $20.8M, up 21% YoY; U.S. revenue $13.9M (+26%); International $6.9M (+12%).
- Net loss $15.3M ($0.39/share) vs $16.2M ($0.43) in Q2 2023; adjusted EBITDA loss $7.6M vs $10.3M.
- Gross margin held at 74%; operating expenses $30.9M, including $1.7M one-time software impairment.
- Added 17 new U.S. Zephyr Valve treatment centers; first U.S. patients treated in AeriSeal CONVERT II trial.
- Full-year 2024 guidance reaffirmed: revenue $81-84M, gross margin 74-75%, opex $127-129M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000073/0001127537-24-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753724000073/lung-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001127537-24-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer